Supported by an Educational Grant from: Mallinckrodt Pharmaceuticals
TITLE - Emerging Therapies and Biomarkers in Rheumatoid Arthritis
TARGET AUDIENCE - Physicians, Rheumatologists, Medical Directors, and other healthcare professionals
LEARNING OBJECTIVES - After completing the program, Physicians along with other healthcare practitioner participants will be able to:
Describe the clinical efficacy and unique properties of the newer TNF inhibitors for treating rheumatoid arthritis.
Describe the distinct mode of action, clinical efficacy and application of tocilizumab in rheumatoid arthritis management.
Describe the novel oral agent, tofacitinib for treating rheumatoid arthritis; understand the mechanism of action and its clinical application.
Discuss the current development of biomarkers for monitoring disease activity and predicting therapeutic response.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Course Release Date 5/3/2016
Course Expiration Date: 4/21/2018
|Activity Number||Credit Amount||Accreditation Period|
|Category 1||2 hours||from May 03, 2016|